Updating results

720 results

Sort: Relevance | Date

Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

Proposed [GID-TA10596] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

Proposed [GID-TA10597] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Technology appraisal guidance Proposed

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]

Proposed [GID-TA10601] Expected publication date: TBC

Technology appraisal guidance Proposed

Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]

Proposed [GID-TA10602] Expected publication date: TBC

Technology appraisal guidance Proposed

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Proposed [GID-TA10603] Expected publication date: TBC

Technology appraisal guidance Proposed

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostemsavir for treating multidrug resistant HIV-1 [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

Proposed [GID-TA10566] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

Proposed [GID-TA10564] Expected publication date: TBC

Technology appraisal guidance Proposed

Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma [ID2708]

Proposed [GID-TA10588] Expected publication date: 24 March 2021

Technology appraisal guidance Proposed

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

Proposed [GID-TA10581] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

Proposed [GID-TA10572] Expected publication date: TBC

Technology appraisal guidance Proposed

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

Proposed [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance Proposed

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

Proposed [GID-TA10568] Expected publication date: TBC

Technology appraisal guidance Proposed

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

Proposed [GID-TA10583] Expected publication date: TBC

Technology appraisal guidance Proposed

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

Proposed [GID-TA10573] Expected publication date: TBC

Technology appraisal guidance Proposed

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance Proposed

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

Proposed [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance Proposed

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

Proposed [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance Proposed

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Inducing labour (Update)

In development [GID-NG10082] Expected publication date: 01 July 2020

NICE guideline In development

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder

In development [GID-MT530] Expected publication date: 01 June 2020

Medical technologies guidance In development

Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma [ID1426]

In development [GID-TA10331] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Lenalidomide for previously treated follicular lymphoma [ID1374]

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Postnatal care

In development [GID-NG10070] Expected publication date: 25 November 2020

NICE guideline In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Implanting a baroreceptor stimulation device for resistant hypertension

In development [GID-IP1180] Expected publication date: TBC

Interventional procedures guidance In development